Advancing Nuclear Medicine

  • Serving 30.000 patients daily
  • 1 hour away from important European airport
  • Europe's most complete nuclear infrastructure

In a nutshell

#1

World leader in research and production of important ingredients for nuclear medicine.

Patiënts per day. This is the amount of people served with medicines from Petten.

1

Hour away from an important European airport. A strategic position for the distribution of nuclear medicine worldwide.

Our solutions

drag for more

The starting material for technetium-99m (Tc-99m) generators. Tc-99m is perhaps the most important isotope in nuclear medicine. Doctors and hospitals use it to diagnose life-threatening diseases, such as cancer. Some 49 million nuclear drug investigations are conducted annually, and Tc-99m is used in more than 80% of these treatments.

The largest supplier of radioactive lutetium-177 worldwide. For the treatment of prostate cancer and neuroendocrine tumors.

The future of medical isotopes in diagnosis and treatment. Supports the development of new nuclear medicines within a unique nuclear infrastructure. Promises the delivery of promising medical services.

The largest area of ​​application of iridium-192 is gynecology, for example for the treatment of cervical cancer.

All products

Some of our success stories

Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.

In 2017, there was suddenly a worldwide shortage of iodine-125, used for brachytherapy for prostate cancer, because one of the large producers was temporarily shut down. McMaster & NRG joined forces for global supply.

A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.

Advancing Nuclear Medicine

FIELD-LAB: an innovative partnership for the development of nuclear medicine!

FIELD-LAB is a partnership that aims to convert knowledge into new medical solutions. The aim is to accelerate the process from development to the production of nuclear therapies for cancer patients.

 

  • Supply of radiochemical solutions and radiofarmaceuticals to laboratories
  • Both research and GMP grade
  • Creation of radiochemical processes using innovative isotopes
  • Collaboration between academic and industrial partners
  • Portal to a fast-growing network with an open innovation culture
FIELD-LAB

Partners & clients around the world

Advancing Nuclear Medicine

NRG Advancing Nuclear Medicine cares for the well-being of people worldwide. Especially for their health. We wish people to live longer, be more vital and feel happier. We believe everybody should have access to advanced treatments. New highly targeted treatments will cause less side effects and improve the quality of life.

We provide solutions to advance nuclear medicine ranging from complete irradiation services for medical isotope production, to access to R&D resources & commercial processing.

About

Publications

A decade ago, it was claimed that alpha-emitters are indispensable when it comes to optimisation of strategies for tumour therapy. Over time, this robust statement has become increasingly relevant, which has resulted in research aiming to develop alpha therapy which can be used in the clinic to substantially improve outcomes for cancer patients. This is exactly what healthcare entrepreneur Jan van Bodegom, MD will present at the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit in Berlin between 7 and 9 December 2021.

In the University of Warwick and King’s College London, the FIELD-LAB of NRG has found its first international partners. Despite the significant barriers created by both the COVID-pandemic and Brexit, researchers and scientists on both sides of the Channel managed to get things started and hope to present exciting new findings in due time. Dr Cinzia Imberti, Sir Henry Wellcome Postdoctoral Fellow, University of Warwick, UK and Nora Klaassen, project manager R&D at Field-Lab, Petten, the Netherlands, shed some light on how this collaboration started and its hopes for the future.

Publications